Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cannon

Showing results (391-400 of 418) with videos related to

Pageof 42
Sort By:
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Emerging Infectious Diseases|April 26, 2021
Global Trends in Norovirus Genotype Distribution among Children with Acute GastroenteritisJennifer L Cannon, Joseph Bonifacio, Filemon Bucardo, et al.
JAMA|October 23, 1997
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testingD Shattuck-Eidens, A Oliphant, M McClure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAjjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
American Journal of Human Genetics|February 1, 1996
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international studyS L Neuhausen, S Mazoyer, L Friedman, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Genomics|August 15, 1996
Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13F J Couch, J M Rommens, S L Neuhausen, et al.
Emerging Infectious Diseases|December 8, 2023
Emergence of Novel Norovirus GII.4 VariantPreeti Chhabra, Damien C Tully, Janet Mans, et al.
The FEBS Journal|January 31, 2025
A cellular model of TDP-43 induces phosphorylated TDP-43 aggregation with distinct changes in solubility and autophagy dysregulationMatthew B Dopler, Muhammad I Abeer, Sanaz Arezoumandan, et al.
Pageof 42

Showing results (391-400 of 418) with videos related to

Sort By:
Pageof 42
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Emerging Infectious Diseases|April 26, 2021
Global Trends in Norovirus Genotype Distribution among Children with Acute GastroenteritisJennifer L Cannon, Joseph Bonifacio, Filemon Bucardo, et al.
JAMA|October 23, 1997
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testingD Shattuck-Eidens, A Oliphant, M McClure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAjjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
American Journal of Human Genetics|February 1, 1996
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international studyS L Neuhausen, S Mazoyer, L Friedman, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Genomics|August 15, 1996
Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13F J Couch, J M Rommens, S L Neuhausen, et al.
Emerging Infectious Diseases|December 8, 2023
Emergence of Novel Norovirus GII.4 VariantPreeti Chhabra, Damien C Tully, Janet Mans, et al.
The FEBS Journal|January 31, 2025
A cellular model of TDP-43 induces phosphorylated TDP-43 aggregation with distinct changes in solubility and autophagy dysregulationMatthew B Dopler, Muhammad I Abeer, Sanaz Arezoumandan, et al.
Pageof 42